|
Name |
palmarumycin CP2
|
| Molecular Formula | C20H14O4 | |
| IUPAC Name* |
8-hydroxyspiro[2,3-dihydronaphthalene-4,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-1-one
|
|
| SMILES |
C1CC2(C3=C(C1=O)C(=CC=C3)O)OC4=CC=CC5=C4C(=CC=C5)O2
|
|
| InChI |
InChI=1S/C20H14O4/c21-14-7-3-6-13-19(14)15(22)10-11-20(13)23-16-8-1-4-12-5-2-9-17(24-20)18(12)16/h1-9,21H,10-11H2
|
|
| InChIKey |
BGMMZNMDIABGHL-UHFFFAOYSA-N
|
|
| Synonyms |
palmarumycin CP2; CHEMBL511169; SCHEMBL10000180; 8-hydroxyspiro[2,3-dihydronaphthalene-4,3'-2,4-dioxatricyclo[7.3.1.05,13]trideca-1(12),5,7,9(13),10-pentaene]-1-one
|
|
| CAS | NA | |
| PubChem CID | 9995992 | |
| ChEMBL ID | CHEMBL511169 |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 318.3 | ALogp: | 4.4 |
| HBD: | 1 | HBA: | 4 |
| Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
| Polar Surface Area: | 55.8 | Aromatic Rings: | 5 |
| Heavy Atoms: | 24 | QED Weighted: | 0.65 |
| Caco-2 Permeability: | -4.924 | MDCK Permeability: | 0.00001880 |
| Pgp-inhibitor: | 0.052 | Pgp-substrate: | 0 |
| Human Intestinal Absorption (HIA): | 0.003 | 20% Bioavailability (F20%): | 0.007 |
| 30% Bioavailability (F30%): | 0.04 |
| Blood-Brain-Barrier Penetration (BBB): | 0.465 | Plasma Protein Binding (PPB): | 97.67% |
| Volume Distribution (VD): | 0.621 | Fu: | 1.14% |
| CYP1A2-inhibitor: | 0.952 | CYP1A2-substrate: | 0.264 |
| CYP2C19-inhibitor: | 0.945 | CYP2C19-substrate: | 0.088 |
| CYP2C9-inhibitor: | 0.912 | CYP2C9-substrate: | 0.934 |
| CYP2D6-inhibitor: | 0.793 | CYP2D6-substrate: | 0.349 |
| CYP3A4-inhibitor: | 0.853 | CYP3A4-substrate: | 0.263 |
| Clearance (CL): | 5.29 | Half-life (T1/2): | 0.521 |
| hERG Blockers: | 0.017 | Human Hepatotoxicity (H-HT): | 0.336 |
| Drug-inuced Liver Injury (DILI): | 0.937 | AMES Toxicity: | 0.959 |
| Rat Oral Acute Toxicity: | 0.707 | Maximum Recommended Daily Dose: | 0.069 |
| Skin Sensitization: | 0.671 | Carcinogencity: | 0.951 |
| Eye Corrosion: | 0.003 | Eye Irritation: | 0.869 |
| Respiratory Toxicity: | 0.702 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002530 | ![]() |
0.753 | D06TJJ | ![]() |
0.352 | ||
| ENC003199 | ![]() |
0.753 | D08CCE | ![]() |
0.287 | ||
| ENC005582 | ![]() |
0.707 | D05VLS | ![]() |
0.269 | ||
| ENC001112 | ![]() |
0.707 | D0H8QL | ![]() |
0.267 | ||
| ENC005583 | ![]() |
0.682 | D06ZEE | ![]() |
0.263 | ||
| ENC005524 | ![]() |
0.682 | D0QV5T | ![]() |
0.262 | ||
| ENC000996 | ![]() |
0.667 | D0Q5UQ | ![]() |
0.261 | ||
| ENC005548 | ![]() |
0.655 | D02TJS | ![]() |
0.259 | ||
| ENC003201 | ![]() |
0.602 | D0L6DA | ![]() |
0.257 | ||
| ENC002038 | ![]() |
0.565 | D0O6IZ | ![]() |
0.255 | ||